[go: up one dir, main page]

NO20084456L - Organiske forbindelser - Google Patents

Organiske forbindelser

Info

Publication number
NO20084456L
NO20084456L NO20084456A NO20084456A NO20084456L NO 20084456 L NO20084456 L NO 20084456L NO 20084456 A NO20084456 A NO 20084456A NO 20084456 A NO20084456 A NO 20084456A NO 20084456 L NO20084456 L NO 20084456L
Authority
NO
Norway
Prior art keywords
organic compounds
stereoisomers
compound
indicated
formula
Prior art date
Application number
NO20084456A
Other languages
English (en)
Inventor
Roger John Taylor
Robin Alec Fairhurst
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20084456L publication Critical patent/NO20084456L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det beskrives en forbindelse med formel (I), eller stereoisomerer eller farmasøytisk akseptable salter derav, (I) der R1a, R1b, R2a,R2b, U1, U2, X1, X2 og L er som angitt.
NO20084456A 2006-04-21 2008-10-22 Organiske forbindelser NO20084456L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0607950.3A GB0607950D0 (en) 2006-04-21 2006-04-21 Organic compounds
PCT/EP2007/003439 WO2007121924A2 (en) 2006-04-21 2007-04-19 Bisadenosine compounds as adenosine a2a receptor agonists

Publications (1)

Publication Number Publication Date
NO20084456L true NO20084456L (no) 2008-12-09

Family

ID=36581047

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084456A NO20084456L (no) 2006-04-21 2008-10-22 Organiske forbindelser

Country Status (32)

Country Link
US (1) US8193164B2 (no)
EP (1) EP2018388B9 (no)
JP (1) JP2009534341A (no)
KR (1) KR20080112399A (no)
CN (1) CN101437829B (no)
AR (1) AR060606A1 (no)
AT (1) ATE502040T1 (no)
AU (1) AU2007241347A1 (no)
CA (1) CA2648037A1 (no)
CL (1) CL2007001132A1 (no)
CR (1) CR10328A (no)
CY (1) CY1111568T1 (no)
DE (1) DE602007013203D1 (no)
DK (1) DK2018388T3 (no)
EC (1) ECSP088837A (no)
ES (1) ES2363255T3 (no)
GB (1) GB0607950D0 (no)
GT (1) GT200800218A (no)
HR (1) HRP20110445T1 (no)
IL (1) IL194398A0 (no)
MA (1) MA30404B1 (no)
MX (1) MX2008013398A (no)
NO (1) NO20084456L (no)
PE (1) PE20071228A1 (no)
PL (1) PL2018388T3 (no)
PT (1) PT2018388E (no)
RU (1) RU2008145715A (no)
SI (1) SI2018388T1 (no)
TN (1) TNSN08409A1 (no)
TW (1) TW200813074A (no)
WO (1) WO2007121924A2 (no)
ZA (1) ZA200808103B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
MX2008012928A (es) 2006-04-04 2009-03-06 Univ California Antagonistas de pi3-cinasa.
PT2013211E (pt) * 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CN101553459A (zh) * 2006-11-10 2009-10-07 诺瓦提斯公司 环戊烯二醇单乙酸酯衍生物
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US20090181934A1 (en) * 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
US20100197914A1 (en) * 2007-10-17 2010-08-05 Robin Alec Fairhurst Purine Derivatives as Adenosine Al Receptor Ligands
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
ES2647163T3 (es) 2008-01-04 2017-12-19 Intellikine, Inc. Derivados de isoquinolinona sustituidos con una purina útiles como inhibidores de la PI3K
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
CA2740885C (en) 2008-10-16 2018-04-03 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
KR20180080358A (ko) 2011-01-10 2018-07-11 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
CA2828483A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014052669A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
DK2914296T4 (da) 2012-11-01 2022-01-03 Infinity Pharmaceuticals Inc Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2900806T3 (es) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6980649B2 (ja) 2015-09-14 2021-12-15 インフィニティー ファーマシューティカルズ， インコーポレイテッド イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1528382A (en) 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4873360A (en) 1986-07-10 1989-10-10 Board Of Governors Of Wayne State University Process for the preparation of cyclopentanoids and novel intermediates produced thereby
IL84414A0 (en) 1986-11-14 1988-04-29 Ciba Geigy Ag N9-cyclopentyl-substituted adenine derivatives
US4954504A (en) 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
JP2586897B2 (ja) 1987-03-09 1997-03-05 富士薬品工業株式会社 光学活性なシス−シクロペンテン−３，５−ジオ−ルモノエステルの製造法
DE69123974T2 (de) 1990-09-25 1997-05-07 Rhone-Poulenc Rorer International (Holdings) Inc., Greenville, Del. Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5691188A (en) 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
EP0909270B1 (en) 1996-01-02 2002-06-26 Aventis Pharmaceuticals Products Inc. Process for preparing 2,4-dihydroxypyridine and 2,4-dihydroxy-3-nitropyridine
US6376472B1 (en) 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
AU750322B2 (en) 1997-05-09 2002-07-18 Trustees Of The University Of Pennsylvania, The Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
AP2000002016A0 (en) 1998-06-23 2000-12-31 Glaxo Group Ltd 2-(Purin-9-yl) Tetrahydrofuran-3,4-diol derivatives.
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
BR9914526A (pt) 1998-10-16 2001-07-03 Pfizer Derivados de adenina
JP2002534430A (ja) 1998-12-31 2002-10-15 アベンティス・ファーマスーティカルズ・プロダクツ・インコーポレイテツド Ｎ６−置換デアザアデノシン誘導体類の製造法
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6586413B2 (en) 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
CA2434906C (en) 2001-01-16 2008-08-19 Can-Fite Biopharma Ltd. Use of an adenosine a3 receptor agonist for inhibition of viral replication
GB2372741A (en) 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
US20040162422A1 (en) 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
EP1258247A1 (en) 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
JP4514452B2 (ja) 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
US20090170803A1 (en) 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
WO2005063246A1 (en) 2003-12-29 2005-07-14 Can-Fite Biopharma Ltd. Method for treatment of multiple sclerosis
US20080221060A1 (en) 2004-03-05 2008-09-11 Martyn Pritchard Therapeutic Compounds
WO2005107463A1 (en) 2004-05-03 2005-11-17 University Of Virginia Patent Foundation Agonists of a2a adenosine receptors for treatment of diabetic nephropathy
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
CA2570698C (en) * 2004-06-23 2013-11-19 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
EP1778239B1 (en) 2004-07-28 2013-08-21 Can-Fite Biopharma Ltd. Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome
AU2005285284B2 (en) 2004-09-09 2011-06-02 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 and A1 adenosine receptor agonists
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US20080051364A1 (en) 2004-11-08 2008-02-28 Pninna Fishman Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
CA2596424C (en) 2005-02-04 2016-03-29 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
GB0505219D0 (en) 2005-03-14 2005-04-20 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2622879C (en) 2005-11-30 2011-07-05 Can-Fite Biopharma Ltd. Use of a3 adenosine receptor agonist in osteoarthritis treatment
ES2360632T3 (es) 2006-01-26 2011-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Moduladores alostéricos del receptor a3 de adenosina.
CN110003216A (zh) 2006-02-02 2019-07-12 千禧药品公司 E1活化酶抑制剂
US20080027022A1 (en) 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
GB0607944D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2013211E (pt) 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CN101553459A (zh) 2006-11-10 2009-10-07 诺瓦提斯公司 环戊烯二醇单乙酸酯衍生物
WO2008124150A1 (en) 2007-04-09 2008-10-16 University Of Virginia Patent Foundation Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en) 2007-04-23 2008-10-23 Adenosine Therapeutics, Llc Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
US8153781B2 (en) 2007-06-29 2012-04-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Dendrimer conjugates of agonists and antagonists of the GPCR superfamily
US20100197914A1 (en) 2007-10-17 2010-08-05 Robin Alec Fairhurst Purine Derivatives as Adenosine Al Receptor Ligands
US20090181934A1 (en) 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
WO2009061516A1 (en) 2007-11-08 2009-05-14 New York University School Of Medicine Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
US20090181920A1 (en) 2008-01-09 2009-07-16 Pgxhealth, Llc Intrathecal treatment of neuropathic pain with a2ar agonists

Also Published As

Publication number Publication date
PL2018388T3 (pl) 2011-08-31
DE602007013203D1 (de) 2011-04-28
GB0607950D0 (en) 2006-05-31
HRP20110445T1 (hr) 2011-07-31
ECSP088837A (es) 2008-11-27
AU2007241347A1 (en) 2007-11-01
EP2018388A2 (en) 2009-01-28
CA2648037A1 (en) 2007-11-01
MA30404B1 (fr) 2009-05-04
CN101437829B (zh) 2012-03-21
EP2018388B9 (en) 2011-10-05
SI2018388T1 (sl) 2011-07-29
GT200800218A (es) 2008-12-15
PT2018388E (pt) 2011-06-27
TNSN08409A1 (en) 2010-04-14
CR10328A (es) 2008-11-18
ATE502040T1 (de) 2011-04-15
TW200813074A (en) 2008-03-16
ZA200808103B (en) 2009-07-29
EP2018388B1 (en) 2011-03-16
AR060606A1 (es) 2008-07-02
RU2008145715A (ru) 2010-05-27
WO2007121924A3 (en) 2008-09-04
ES2363255T3 (es) 2011-07-28
PE20071228A1 (es) 2008-01-24
JP2009534341A (ja) 2009-09-24
US20100190784A1 (en) 2010-07-29
CY1111568T1 (el) 2015-10-07
MX2008013398A (es) 2008-11-04
WO2007121924A2 (en) 2007-11-01
US8193164B2 (en) 2012-06-05
IL194398A0 (en) 2009-08-03
DK2018388T3 (da) 2011-06-27
CL2007001132A1 (es) 2008-05-23
KR20080112399A (ko) 2008-12-24
CN101437829A (zh) 2009-05-20

Similar Documents

Publication Publication Date Title
NO20084456L (no) Organiske forbindelser
TNSN08407A1 (en) Organic compounds
EA200801381A1 (ru) Производные пиримидина
MA32456B1 (fr) Dérivé hétérocyclique contenant du soufre ayant une activité inhibant la b-sécrétase
NO20054224L (no) Nye 2-pyridinkarboksamidderivater
NO20084583L (no) Makrosykliske kinase-inhibitorer
NO20076624L (no) Syklisk aminderivat med substituert alkylgruppe
NO20076054L (no) Imidiazo - og triazolopyridiner som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase type I
JO2681B1 (en) Indole derivatives
ECSP088367A (es) Derivados de bifenilo y su uso en el tratamiento de la hepatitis c
TW201129556A (en) Novel antiplatelet agent
NO20076055L (no) Imidazo- og triazolopyridiner som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase type I
NO20075768L (no) Hydroksybenzamidderivater og deres anvendelse som inhibitorer av HSP90
WO2008146665A1 (ja) 有機エレクトロルミネッセンス素子用材料及び有機エレクトロルミネッセンス素子並びに有機エレクトロルミネッセンス表示装置
WO2009020140A1 (ja) アダマンチルウレア誘導体
NO20082209L (no) Homo- og heterocykliske forbindelser anvendbare som CETP-inhibitorer
DK2279187T3 (da) Spirocykliske derivater som histondeacetylaseinhibitorer
MX2009011365A (es) Compuestos anulares de seis miembros en puente.
NO20082877L (no) Forloperforbindelse til radioaktiv halogenmerket organisk forbindelse
NO20081888L (no) Triazolforbindelser som lipoksygenaseinhibitorer
EA201070138A1 (ru) Производные плевромутилина и их применение в качестве антимикробных средств
MX2009009525A (es) Activador de glucocinasa.
MX2009012125A (es) Compuestos terapeuticos.
MX2009012222A (es) Dihidroquinonas y dihidronaftiridinas como inhibidores de las quinasas c-jun-n-terminales.
EA200970373A1 (ru) АНТИДЕПРЕССАНТ, НЕЙРОПРОТЕКТОР, ИНГИБИТОР ОТЛОЖЕНИЙ β-АМИЛОИДА ИЛИ СРЕДСТВО, ЗАМЕДЛЯЮЩЕЕ СТАРЕНИЯ, СОДЕРЖАЩИЕ ГЕТЕРОЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ КОНКРЕТНОЙ СТРУКТУРЫ

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application